FOR IMMEDIATE RELEASE
SYNDEO Medical today announced that its SATURN2 Rapid Inflation Device has received EU MDR certification under Regulation (EU) 2017/745, enabling commercial availability across European markets. SATURN2 is available in both 30 atmosphere and 40 atmosphere configurations, as well as in round and T handle formats, offering flexible options aligned with procedural requirements across a range of interventional applications.
SATURN2 is a rapid inflation device platform designed to support controlled, responsive inflation during various interventional procedures. It reflects SYNDEO Medical’s strategy of delivering devices that function effectively as standalone products while also integrating into broader procedural solutions when required.
The SATURN2 rapid inflation technology is engineered with high frequency users in mind. The device is designed for repeated inflation use, with intuitive handling and mechanics that align naturally with human biomechanics. This design approach supports sustainable workflows in demanding procedural environments.
“This is a very significant commercial milestone for SYNDEO Medical,” said A. Justin Lampropoulos, CEO and Founder of SYNDEO Medical. “SATURN2 was engineered deliberately, feature by feature, with a genuine purpose behind every design decision. From the two shot trigger mechanism to the rapid inflation technology and the overall form and aesthetics of the device, nothing was incidental. We focused on how the device is actually used in real interventional settings and built SATURN2 to support efficiency, repeatability, and sustained use. The result is a rapid inflation device that serves as a versatile inflation device platform across multiple interventional procedures.”
SATURN2 will be available through SYNDEO Medical’s global independent distribution partners, will be offered through select procedure pack producers across Europe in the near future, and is also available for original equipment manufacturer (OEM) collaborations. The device will be showcased at the upcoming MD&M West conference in Anaheim, California, taking place 3 to 5 February 2026.
SYNDEO Medical designs, develops, and distributes fully integrated and custom procedural solution products for minimally invasive interventional and surgical care. Founded in 2023 by A. Justin Lampropoulos and headquartered in Belgium, the company serves health care providers worldwide through a network of distribution partners and sales representatives. SYNDEO Medical is committed to improving procedural efficiency, elevating patient experience, and empowering better outcomes.
